US 11,655,304 B2
Antibody and checkpoint inhibitor combination therapy
Tina Christine Lavranos, Thebarton (AU); Daniel John Inglis, Thebarton (AU); and Christopher L. Reyes, Thebarton (AU)
Assigned to Bionomics Limited, Eastwood (AU)
Appl. No. 16/333,065
Filed by Bionomics Limited, Eastwood (AU)
PCT Filed Sep. 14, 2017, PCT No. PCT/AU2017/050998
§ 371(c)(1), (2) Date Mar. 13, 2019,
PCT Pub. No. WO2018/049474, PCT Pub. Date Mar. 22, 2018.
Claims priority of application No. 2016903724 (AU), filed on Sep. 16, 2016.
Prior Publication US 2019/0263925 A1, Aug. 29, 2019
Int. Cl. C07K 16/30 (2006.01); A61P 35/00 (2006.01); A61K 31/343 (2006.01); A61K 31/4741 (2006.01); A61K 31/513 (2006.01); A61K 31/519 (2006.01); A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61K 45/06 (2006.01); A61K 31/661 (2006.01); A61K 31/4745 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/30 (2013.01) [A61K 31/343 (2013.01); A61K 31/4741 (2013.01); A61K 31/4745 (2013.01); A61K 31/513 (2013.01); A61K 31/519 (2013.01); A61K 31/661 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 16/28 (2013.01); C07K 16/2818 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61K 2039/545 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01)] 11 Claims
 
1. A method of treating a colorectal tumour in a subject, wherein the tumor comprises cancer stem cells that express LGR5, the method comprising a combination therapy comprising administration of (i) an antibody directed against leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), wherein the antibody comprises a heavy chain CDR1 having amino acids GYSFTAYW (SEQ ID NO:1), a heavy chain CDR2 having amino acids ILPGSDST (SEQ ID NO:2), a heavy chain CDR3 having amino acids ARSGYYGSSQY (SEQ ID NO:3), a light chain CDR1 having amino acids ESVDSYGNSF (SEQ ID NO:4), a light chain CDR2 having amino acids LTS (SEQ ID NO:5), and a light chain CDR3 having amino acids QQNAEDPRT (SEQ ID NO:6), and (ii) a checkpoint inhibitor, wherein the inhibitor is an antibody that binds to PD-1.